Trametinib (DMSO solvate) is primarily used in cancer research and treatment, specifically targeting melanoma and other cancers with mutations in the MAPK pathway. It functions as a MEK inhibitor, blocking the activity of proteins involved in cancer cell growth and proliferation. This compound is often utilized in preclinical studies to evaluate its efficacy in inhibiting tumor progression and enhancing the effectiveness of combination therapies. In clinical settings, it is administered to patients with BRAF V600 mutation-positive cancers, often in combination with other targeted therapies, to improve treatment outcomes. Additionally, Trametinib (DMSO solvate) is employed in laboratory experiments to study cellular signaling pathways and develop novel therapeutic strategies for various malignancies.